PAREXEL Academy Adds Programs for Students
Three new academic programs have been added to the PAREXEL Academy which span the globe and are designed to prepare students for careers in the biopharmaceutical industry.
Three new academic programs have been added to the PAREXEL Academy which span the globe and are designed to prepare students for careers in the biopharmaceutical industry:
·Bachelor of Science Degree in Clinical Research – Offered in partnership with the Medical School Berlin, in Berlin, Germany, the degree program features courses specific to clinical research. Courses range from ethics in health and medicine to conducting clinical trials. Several courses are taught by PAREXEL experts.
·Postgraduate Certificate in Clinical Trial Management – In cooperation with Salem State University in Salem, Massachusetts, the postgraduate certificate program features a broad-based curriculum in various components of the full life cycle of drug development.
·Joint Program for Clinical Research and Clinical Trial Management – In collaboration with Kyoto Pharmaceutical University in Kyoto, Japan, the joint program provides fifth grade undergraduate students an introductory, seven-week course in clinical research and clinical trial management.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
